Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
Matthew S. Davids(Dana-Farber Cancer Institute), Yifan Zhai(Unknown), Boyd Mudenda, Tanya Siddiqi(City Of Hope National Medical Center), Ivan Muzhychuk, Allison Winter(Cleveland Clinic), Asher Chanan‐Khan(WinnMed), Hengbang Wang, Vinod Ganju(Peninsula Health), Б. А. Бакиров(Bashkir State Medical University), Zi Chen(Central South University), Mohammad Ahmad, Ganna Usenko(Regional Clinical Hospital named after II Mechnikov), Asit K. De, Divya J. Mekala(Vifor Pharma (United States)), Iurii Osipov, Dajun Yang, Iryna Kryachok(National Cancer Institute), Sikander Ailawadhi(Jacksonville College), Alexander G. Myasnikov(Petrozavodsk State University), Zhiyan Liang(East China University of Science and Technology), Olena Kyselova, Vladimir Ivanov(Federal Almazov North-West Medical Research Centre), Paula Marlton(The University of Queensland), Elena Borisenkova(Murmansk Regional Clinical Hospital), Andrei Proydakov(Institute of Chemistry, Komi Science Center), Larysa Nogaieva(Cherkasy State Technological University), Tamila Lysa, Tetiana Perekhrestenko, Mingyu Li, Т. С. Константинова(Regional Children's Clinical Hospital No. 1), Olga Samoilova, Olena Karpenko(Kyiv City Clinical Oncology Center), Nashat Gabrail(Gabrail Cancer Center), L.M. Lukavetsky(Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine), Olga Uspenskaya, Tommy Fu
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k